| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/INFDIS/161.4.618 |
| P698 | PubMed publication ID | 2181028 |
| P2093 | author name string | Wang SP | |
| Saikku P | |||
| Grayston JT | |||
| Mordhorst CH | |||
| Kuo CC | |||
| Campbell LA | |||
| Thom DH | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Chlamydia pneumoniae | Q62869737 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 618-625 | |
| P577 | publication date | 1990-04-01 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. | |
| P478 | volume | 161 |
| Q57816571 | : An Etiologic Agent for Late-Onset Dementia |
| Q90662703 | A Chlamydia pneumoniae adhesin induces phosphatidylserine exposure on host cells |
| Q37868503 | A Prospective Study of Chlamydia pneumoniae Antibodies in Children Between 7 months and 8 years of Age |
| Q37859461 | A clinically silent respiratory infection with Chlamydophila spp. in calves is associated with airway obstruction and pulmonary inflammation. |
| Q37869625 | A lack of serologic evidence of transmission of Chlamydia pneumoniae by transfusion of buffy coat‐depleted RBCs |
| Q33596734 | A mouse model of Chlamydia pneumoniae strain TWAR pneumonitis |
| Q37885832 | A new primer pair for detection of Chlamydia pneumoniae by polymerase chain reaction |
| Q34082096 | A protein secreted by the respiratory pathogen Chlamydia pneumoniae impairs IL-17 signalling via interaction with human Act1 |
| Q58601477 | A retrospective seroepidemiologic survey of Chlamydia pneumoniae infection in patients in Beijing between 2008 and 2017 |
| Q37885733 | A seroepidemiologic study of Chlamydia pneumoniae, Chlamydia trachomatis and Chlamydia psittaci in different populations on the mainland of China |
| Q37871487 | Absence of Chlamydia pneumoniae in surgical specimens of coronary and carotid arteries by polymerase chain reaction |
| Q37878072 | Activity of grepafloxacin and other fluoroquinones and newer macrolides against recent clinical isolates of Chlamydia pneumoniae |
| Q33770135 | Activity of quinolones against Chlamydia pneumoniae |
| Q37859047 | Acute exacerbation of idiopathic pulmonary fibrosis: role of Chlamydophila pneumoniae infection |
| Q37891752 | Acute lower respiratory tract infection associated with Chlamydia pneumoniae in Germany |
| Q33584099 | Aetiological role of bacteria associated with reactive arthritis in pauciarticular juvenile chronic arthritis |
| Q33715950 | Age alterations in extent and severity of experimental intranasal infection with Chlamydophila pneumoniae in BALB/c mice |
| Q37889685 | Age specific prevalence of antibodies against Chlamydia pneumoniae in Iceland |
| Q98224831 | An Ancient Molecular Arms Race: Chlamydia vs. Membrane Attack Complex/Perforin (MACPF) Domain Proteins |
| Q33997961 | Analysis of the humoral immune response to Chlamydia pneumoniae by immunoblotting and immunoprecipitation. |
| Q37869913 | Anti-Chlamydia pneumoniae heat shock protein 10 antibodies in asthmatic adults |
| Q37875140 | Antibiotic therapy for treatment of Chlamydia to prevent coronary heart disease events |
| Q35587190 | Antibiotic treatment of atherosclerosis |
| Q37888465 | Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae |
| Q28195798 | Aspirin inhibits Chlamydia pneumoniae-induced NF-κB activation, cyclo-oxygenase-2 expression and prostaglandin E2 synthesis and attenuates chlamydial growth |
| Q36259587 | Association between Chlamydia pneumoniae IgG antibodies and migraine |
| Q36225330 | Association between Chlamydia pneumoniae antibodies and wheezing in young children and the influence of sex. |
| Q37877118 | Association of Chlamydia pneumoniae infection with diabetic nephropathy |
| Q44460600 | Association of Mycoplasma pneumoniae and asthma among Indian children. |
| Q37865490 | Association of raised titres of antibodies to Chlamydia pneumoniae with a history of pre-eclampsia |
| Q37878633 | Asthma, atopy and Chlamydia pneumoniae antibodies in adults |
| Q37243062 | Asymptomatic respiratory tract infection with Chlamydia pneumoniae TWAR |
| Q37883441 | Atypical respiratory pathogens |
| Q40579081 | Bronchoscopic diagnosis of pneumonia |
| Q92061404 | Bronconeumopatías agudas del niño |
| Q61798484 | CPn0572, the C. pneumoniae ortholog of TarP, reorganizes the actin cytoskeleton via a newly identified F-actin binding domain and recruitment of vinculin |
| Q33597752 | Cell-mediated immunity to Chlamydia pneumoniae measured as lymphocyte blast transformation in vitro. |
| Q37335962 | Characterization of the interaction between the chlamydial adhesin OmcB and the human host cell |
| Q37885974 | Chlamydia pneumoniae (TWAR) infection in Tanzanian children |
| Q37889646 | Chlamydia pneumoniae (TWAR): a common agent in acute bronchitis |
| Q37894361 | Chlamydia pneumoniae (strain TWAR) isolated from two symptom-free children during evaluation for possible sexual assault |
| Q89697993 | Chlamydia pneumoniae Influence on Cytokine Production in Steroid-Resistant and Steroid-Sensitive Asthmatics |
| Q37869704 | Chlamydia pneumoniae affect surfactant trafficking and secretion due to changes of type II cell cytoskeleton |
| Q37887835 | Chlamydia pneumoniae and Chronic Pharyngitis |
| Q37878540 | Chlamydia pneumoniae and Mycoplasma pneumoniae pneumonia in children |
| Q35532326 | Chlamydia pneumoniae and asthma |
| Q33905858 | Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies |
| Q37880928 | Chlamydia pneumoniae and exacerbations of asthma in adults |
| Q37849596 | Chlamydia pneumoniae and helicobacter pylori serology - importance in patients with coronary heart disease |
| Q37881193 | Chlamydia pneumoniae and its role in chronic obstructive pulmonary disease |
| Q37867013 | Chlamydia pneumoniae and newly diagnosed asthma: a case-control study in 1 to 6-year-old children |
| Q37880994 | Chlamydia pneumoniae and occlusive vascular disease: identification and characterization |
| Q37880177 | Chlamydia pneumoniae and vascular disease |
| Q37240380 | Chlamydia pneumoniae elementary body antigenic reactivity with fluorescent antibody is destroyed by methanol |
| Q37878264 | Chlamydia pneumoniae in a free-ranging giant barred frog (Mixophyes iteratus) from Australia. |
| Q37874692 | Chlamydia pneumoniae in children undergoing adenoidectomy. |
| Q37878342 | Chlamydia pneumoniae infection and atherosclerotic coronary disease |
| Q37878142 | Chlamydia pneumoniae infection and ethnic origin |
| Q37871138 | Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis |
| Q34481798 | Chlamydia pneumoniae infection enhances cellular proliferation and reduces steroid responsiveness of human peripheral blood mononuclear cells via a tumor necrosis factor-alpha-dependent pathway |
| Q34000720 | Chlamydia pneumoniae infection in human monocytes |
| Q33877198 | Chlamydia pneumoniae infection in polarized epithelial cell lines |
| Q37853142 | Chlamydia pneumoniae infection suppresses Staphylococcus enterotoxin B-induced proliferation associated with down-expression of CD25 in lymphocytes |
| Q37895606 | Chlamydia pneumoniae infections in Norway 1981-87 earlier diagnosed as ornithosis |
| Q35627745 | Chlamydia pneumoniae infections in asthma: clinical implications. |
| Q37871890 | Chlamydia pneumoniae infections in patients with community-acquired pneumonia in Slovenia. |
| Q34009858 | Chlamydia pneumoniae infects and multiplies in lymphocytes in vitro |
| Q37877800 | Chlamydia pneumoniae is an important cause of community-acquired pneumonia in school-aged children: serological results of a prospective, population-based study |
| Q37878307 | Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms |
| Q37859568 | Chlamydia pneumoniae respiratory infections in Taiwan |
| Q37895602 | Chlamydia pneumoniae respiratory tract infection: the interpretation of high titres in the complement fixation test |
| Q37871330 | Chlamydia pneumoniae seropositivity and early carotid atherosclerosis in a suburban Japanese population |
| Q36292173 | Chlamydia pneumoniae seroprevalence in immunocompetent and immunocompromised populations in Milan |
| Q33763030 | Chlamydia pneumoniae, asthma, and COPD: what is the evidence? |
| Q33566092 | Chlamydia pneumoniae--a new causative agent of reactive arthritis and undifferentiated oligoarthritis |
| Q37880847 | Chlamydia pneumoniae-specific cell-mediated and humoral immunity in healthy people |
| Q43422370 | Chlamydia pneumoniae: another agent added to the growing list of transfusion-transmitted pathogens? |
| Q37878350 | Chlamydia trachomatis and male infertility: chlamydia-IgA antibodies in seminal plasma are C. trachomatis specific and associated with an inflammatory response |
| Q43428225 | Chlamydia: a role for multiple sclerosis or more confusion? |
| Q37877962 | Chlamydial antibodies in an elderly Finnish population |
| Q37887496 | Chlamydial envelope components and pathogen-host cell interactions |
| Q37889397 | Chlamydial etiology of acute lower respiratory tract infections in children in the Sudan |
| Q68613645 | Chlamydial infections |
| Q35660343 | Chlamydial infections of the heart |
| Q33778482 | Chlamydial lipopolysaccharide |
| Q37864015 | Chlamydophila pneumoniae and Mycoplasma pneumoniae in respiratory specimens of children with chronic lung diseases |
| Q38487699 | Chlamydophila pneumoniae enhances secretion of VEGF, TGF-beta and TIMP-1 from human bronchial epithelial cells under Th2 dominant microenvironment |
| Q33843633 | Chronic infection and coronary artery disease |
| Q79299394 | Chronic infection and coronary artery disease |
| Q46840064 | Chronic pharyngitis: role of atypical organisms: a case control study from South India |
| Q37864193 | Clearance of Chlamydia pneumoniae infection in H-2 class I human leucocyte antigen-A2.1 monochain transgenic mice |
| Q37885334 | Clinical features of Chlamydia pneumoniae acute respiratory infection |
| Q37885757 | Clinical manifestations of Chlamydia pneumoniae infections |
| Q36512610 | Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia |
| Q34382834 | Community-acquired pneumonia in ambulatory patients: relative importance of atypical pathogens |
| Q37838935 | Comparative genomic analysis of human Chlamydia pneumoniae isolates from respiratory, brain and cardiac tissues |
| Q37095262 | Comparison of Chlamydia pneumoniae isolates by western blot (immunoblot) analysis and DNA sequencing of the omp 2 gene. |
| Q34203352 | Comparison of eleven commercial tests for Chlamydia pneumoniae-specific immunoglobulin G in asymptomatic healthy individuals |
| Q37866926 | Comparison of five PCR assays for detecting Chlamydophila pneumoniae DNA. |
| Q33998580 | Comparison of five serologic tests for diagnosis of acute infections by Chlamydia pneumoniae |
| Q34781808 | Comparison of quantitative and semiquantitative enzyme-linked immunosorbent assays for immunoglobulin G against Chlamydophila pneumoniae to a microimmunofluorescence test for use with patients with respiratory tract infections |
| Q21266688 | Construction of a highly flexible and comprehensive gene collection representing the ORFeome of the human pathogen Chlamydia pneumoniae |
| Q33974569 | Coronary angioplasty induces rise in Chlamydia pneumoniae-specific antibodies |
| Q33572320 | Cost-effective treatment of lower respiratory tract infections |
| Q43423386 | Culturing Chlamydophila pneumoniae |
| Q36901917 | Current trends in bacterial respiratory pathogens |
| Q37877605 | De Novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model. |
| Q37875816 | Decontamination of a Mycoplasma-infected Chlamydia pneumoniae strain by pulmonary passage in SCID mice |
| Q37873684 | Demonstration of Chlamydia pneumoniae in atherosclerotic arteries from various vascular regions |
| Q37883633 | Demonstration of Chlamydia pneumoniae in patients with chronic pharyngitis |
| Q37883353 | Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms |
| Q34042489 | Depletion of resident Chlamydia pneumoniae through leukoreduction by filtration of blood for transfusion |
| Q37214056 | Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications |
| Q68295810 | Detection of Chlamydia pneumoniae |
| Q43420141 | Detection of Chlamydia pneumoniae DNA in the coronary arteries and bypass in three patients with diffuse coronary artery disease. |
| Q37893831 | Detection of Chlamydia pneumoniae by polymerase chain reaction |
| Q37888492 | Detection of Chlamydia pneumoniae in clinical specimens by polymerase chain reaction using nested primers |
| Q36087554 | Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection |
| Q37884866 | Detection of serum antibodies against Chlamydia pneumoniae by in vitro neutralization and microimmunofluorescence assays. |
| Q34569173 | Development of conventional and real-time nucleic acid sequence-based amplification assays for detection of Chlamydophila pneumoniae in respiratory specimens |
| Q37883879 | Diagnosis of chlamydial infection in the pediatric population |
| Q33749681 | Diagnostic testing for community-acquired pneumonia |
| Q37074513 | Diagnostic utility of PCR-enzyme immunoassay, culture, and serology for detection of Chlamydia pneumoniae in symptomatic and asymptomatic patients |
| Q37880661 | Differentiation of Chlamydia species by combined use of polymerase chain reaction and restriction endonuclease analysis |
| Q36536779 | Differentiation of Chlamydia spp. by sequence determination and restriction endonuclease cleavage of RNase P RNA genes |
| Q37854835 | Effects of CD14, TLR2, TLR4, LPB, and IL-6 gene polymorphisms on Chlamydia pneumoniae growth in human macrophages in vitro. |
| Q35110637 | Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis |
| Q37883374 | Evaluation of Chlamydia immunoglobulin M (IgM), IgG, and IgA rELISAs Medac for diagnosis of Chlamydia pneumoniae infection |
| Q33999796 | Evaluation of Chlamydia pneumoniae 43- and 53-kilodalton recombinant proteins for serodiagnosis by Western Blot |
| Q34943465 | Evaluation of Chlamydia pneumoniae and Mycoplasma pneumoniae as etiologic agents of persistent cough in adolescents and adults. |
| Q37864659 | Evaluation of lung function in pigs either experimentally or naturally infected with Chlamydiaceae |
| Q37890204 | Evaluation of serological methods in the diagnosis of Chlamydia pneumoniae pneumonia during an epidemic in Finland |
| Q37878198 | Evidence of 2 waves of Chlamydia pneumoniae infection in Gävle, Sweden, 1990-96. |
| Q35625261 | Evolutionary relationships among members of the genus Chlamydia based on 16S ribosomal DNA analysis |
| Q37887313 | Experimental Chlamydia pneumoniae infection in mice: effect of reinfection and passive immunization |
| Q35774105 | Experimental rabbit models of Chlamydia pneumoniae infection |
| Q37883033 | Exposures to Legionella pneumophila and Chlamydia pneumoniae in South African Mine Workers |
| Q37880853 | Fundamentals of clinical methodology: 2. Etiology |
| Q37887875 | Further characterization of Chlamydia pneumoniae specific monoclonal antibodies |
| Q37890113 | Growth in serum-free medium improves isolation of Chlamydia pneumoniae |
| Q33821315 | Helicobacter pylori, Chlamydia pneumoniae, and cytomegalovirus: chronic infections and coronary heart disease |
| Q37883688 | High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement |
| Q37869178 | High prevalence of Chlamydia pneumoniae antibodies in white-coat hypertensives |
| Q36503604 | High prevalence of antibodies to Chlamydia pneumoniae; determinants of IgG and IgA seropositivity among Jerusalem residents |
| Q37893957 | Hilar lymphadenopathy associated with Chlamydia pneumoniae infection |
| Q37866443 | Histopathologic signs for the inflammatory role of Chlamydia pneumoniae in the high-grade atherosclerotic coronary artery wall. |
| Q34136991 | How can a causal role for small bacteria in chronic inflammatory arthritides be established or refuted? |
| Q35005258 | Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis - a critical review |
| Q37872162 | Hyperhomocyst(e)inemia and Chlamydia pneumoniae IgG seropositivity in patients with coronary artery disease |
| Q37833851 | Hypothetical protein Cpn0423 triggers NOD2 activation and contributes to Chlamydia pneumoniae-mediated inflammation |
| Q37118408 | Identification of Chlamydia pneumoniae by DNA amplification of the 16S rRNA gene |
| Q34125106 | Identification of Chlamydia pneumoniae-derived mouse CD8 epitopes |
| Q37889915 | Identification of Chlamydia pneumoniae-specific protein antigens in immunoblots |
| Q37862860 | Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae. |
| Q37878292 | Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. |
| Q37884075 | Immunohistochemical detection of Chlamydia pneumoniae in abdominal aortic aneurysms |
| Q37875668 | Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease |
| Q37885660 | Immunopathogenesis of Chlamydia pneumoniae Infections in children |
| Q37888833 | In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae |
| Q35885610 | In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae |
| Q35121993 | In vitro activities of azithromycin, clarithromycin, erythromycin, and tetracycline against 13 strains of Chlamydia pneumoniae |
| Q37893696 | In vitro activities of five quinolones against Chlamydia pneumoniae |
| Q34141733 | In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA. |
| Q37877492 | In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae. |
| Q37874904 | In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis |
| Q37881176 | In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. |
| Q35138264 | In vitro activity of trovafloxacin against Chlamydia pneumoniae |
| Q35136707 | In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. |
| Q35811943 | In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents |
| Q37883558 | In vitro infection of smooth muscle cells by Chlamydia pneumoniae. |
| Q36524413 | In vitro susceptibility of human vascular wall cells to infection with Chlamydia pneumoniae |
| Q37877336 | In-vitro activity of gatifloxacin against Chlamydia trachomatis and Chlamydia pneumoniae |
| Q37883200 | Infection of Acanthamoeba castellanii by Chlamydia pneumoniae |
| Q33921219 | Infections and atherosclerosis |
| Q35079371 | Infectious agents and multiple sclerosis--are Chlamydia pneumoniae and human herpes virus 6 involved? |
| Q72392463 | Infectious diseases |
| Q28194382 | Inflammation and infection in clinical stroke |
| Q37860389 | Inflammatory responses following Chlamydia pneumoniae infection of glial cells |
| Q37871579 | Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model |
| Q37869167 | Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae |
| Q37861388 | Interaction between Chlamydia pneumoniae seropositivity, inflammation and risk factors for atherosclerosis in patients with severe coronary stenosis. |
| Q37879844 | Interaction of Chlamydia pneumoniae and human alveolar macrophages: infection and inflammatory response |
| Q37877539 | Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis |
| Q37881093 | Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease |
| Q37865312 | Intermittent azithromycin treatment for respiratory symptoms in patients with chronic Chlamydia pneumoniae infection |
| Q37861417 | Involvement of TNFalpha -308A promoter polymorphism in the development of asthma in children infected with Chlamydophila pneumoniae. |
| Q43424830 | Is Chlamydia pneumoniae important in asthma? The first controlled trial of therapy leaves the question unanswered |
| Q33603398 | Is cardiovascular disease preventable by vaccination? |
| Q35774875 | Isolation and characterization of a gene encoding a Chlamydia pneumoniae 76-kilodalton protein containing a species-specific epitope |
| Q43415336 | Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer |
| Q37877652 | Lack of association between serum antibodies to Chlamydia trachomatis and a history of recurrent pregnancy loss |
| Q37877084 | Lack of correlation between Chlamydia pneumoniae antibody titers and adult-onset asthma |
| Q37881046 | Lack of correlation between the detection of Chlamydia trachomatis DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an antichlamydial immune response |
| Q37890147 | Lack of evidence of Chlamydia pneumoniae infection in infants with acute lower respiratory tract disease |
| Q36961524 | Limited role for C. pneumoniae, CMV and HSV-1 in cerebral large and small vessel atherosclerosis |
| Q35228122 | Limits of the microimmunofluorescence test and advantages of immunoblotting in the diagnosis of chlamydiosis |
| Q37873990 | Low iron availability modulates the course of Chlamydia pneumoniae infection |
| Q37853983 | Low mannose-binding lectin levels and MBL2 gene polymorphisms associate with Chlamydia pneumoniae antibodies. |
| Q90675908 | Low-Dose Aspirin May Prevent Trophoblast Dysfunction in Women With Chlamydia Pneumoniae Infection |
| Q37887196 | Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease |
| Q33853043 | Markers of inflammation as predictors in cardiovascular disease |
| Q35224726 | Measurement of sputum antibodies in the diagnosis of acute and chronic respiratory infections associated with Chlamydia pneumoniae |
| Q34505586 | Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium |
| Q37881682 | Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. |
| Q37876262 | Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae |
| Q37883424 | Molecular cloning, sequence analysis and functional characterization of the gene kdsA, encoding 3-deoxy-D-manno-2-octulosonate-8-phosphate synthase of Chlamydia psittaci 6BC. |
| Q24561668 | Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients |
| Q30168460 | Mutagenesis and functional reconstitution of chlamydial major outer membrane proteins: VS4 domains are not required for pore formation but modify channel function |
| Q38693771 | Neuroinflammation and Infection: Molecular Mechanisms Associated with Dysfunction of Neurovascular Unit. |
| Q56883926 | New and emerging infectious diseases |
| Q30821899 | Newly characterized species-specific immunogenic Chlamydophila pneumoniae peptide reactive with murine monoclonal and human serum antibodies |
| Q24804167 | Non-detection of Chlamydia species in carotid atheroma using generic primers by nested PCR in a population with a high prevalence of Chlamydia pneumoniae antibody |
| Q33749721 | Nonresolving or slowly resolving pneumonia |
| Q33963149 | Optimizing culture of Chlamydia pneumoniae by using multiple centrifugations |
| Q37860970 | Outbreak of Chlamydia pneumoniae infection in a Japanese nursing home, 1999-2000. |
| Q37892941 | Outbreak of Chlamydia pneumoniae infection in four farm families |
| Q43429081 | Outbreak of chlamydia infection in rural Australian town |
| Q37865610 | Pathohistological changes in diffuse coronary atherosclerosis and chronic infection caused by Chlamydia pneumonia |
| Q37888974 | Performance of three commercially available monoclonal reagents for confirmation of Chlamydia pneumoniae in cell culture. |
| Q37871661 | Performance of three microimmunofluorescence assays for detection of Chlamydia pneumoniae immunoglobulin M, G, and A antibodies |
| Q33672332 | Persistent Chlamydia Pneumoniae serology is related to decline in lung function in women but not in men. Effect of persistent Chlamydia pneumoniae infection on lung function |
| Q37885849 | Persistent Chlamydia pneumoniae infection in a Swedish family |
| Q35547839 | Pneumonia due to Chlamydia pneumoniae in children: Epidemiology, diagnosis, and treatment |
| Q37839743 | Prevalence and characterization of Chlamydia DNA in zoo animals in Japan |
| Q33788646 | Prevalence and persistence of Chlamydia pneumoniae antibodies in healthy laboratory personnel in Finland |
| Q33998574 | Prevalence of Chlamydia pneumoniae and Mycoplasma pneumoniae immunoglobulin G and A antibodies in a healthy Finnish population as analyzed by quantitative enzyme immunoassays |
| Q37893843 | Prevalence of Chlamydia pneumoniae antibodies in Hungary |
| Q37883379 | Prevalence of positive serology for acute Chlamydia pneumoniae infection in emergency department patients with persistent cough |
| Q33688588 | Prevalence of specific antibodies to Chlamydia pneumoniae in Korea |
| Q37876806 | Protective DNA immunization against Chlamydia pneumoniae |
| Q33756547 | Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice |
| Q33428579 | Qualitative and quantitative detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid from multiple sclerosis patients and controls |
| Q37871871 | Quantitative detection of respiratory Chlamydia pneumoniae infection by real-time PCR. |
| Q37883934 | Rabbit model for Chlamydia pneumoniae infection |
| Q37887640 | Rapid diagnosis of chlamydial respiratory infection in children |
| Q37851037 | Recent Chlamydia pneumoniae infection is highly associated with active ankylosing spondylitis in a Chinese cohort |
| Q37893913 | Regional differences of Chlamydia pneumoniae as causative agent of pneumonia in Sweden |
| Q35488540 | Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells |
| Q54277084 | Resistance to Erythromycin in Group A Streptococci |
| Q37888234 | Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult outpatients |
| Q37885893 | Respiratory infections: community-acquired pneumonia and newer microbes |
| Q34698619 | Review of evidence for a connection between Chlamydia pneumoniae and atherosclerotic disease |
| Q36980187 | Review: variability of host-pathogen interaction |
| Q37868255 | Role of Chlamydia pneumoniae and Mycoplasma pneumoniae as Causative Agents of Community-Acquired Pneumonia in Hospitalised Children and Adolescents |
| Q22305814 | Role of Infection in the Pathogenesis of Alzheimerʼs Disease |
| Q37862475 | Role of Mycoplasma pneumoniae and Chlamydia pneumoniae in children with community-acquired pneumonia in Istanbul, Turkey |
| Q37870412 | Role of viruses and atypical bacteria in exacerbations of asthma in hospitalized children: a prospective study in the Nord-Pas de Calais region (France). |
| Q34004010 | Roles of interleukin-12 and gamma interferon in murine Chlamydia pneumoniae infection |
| Q21563468 | Secondary outcomes of a pilot randomized trial of azithromycin treatment for asthma |
| Q37889535 | Selective translocation of annexins during intracellular redistribution of Chlamydia trachomatis in HeLa and McCoy cells. |
| Q37574026 | Self-reported prior lung diseases as risk factors for non-small cell lung cancer in Mexican Americans. |
| Q36961827 | Sequence analysis of the gene encoding the Chlamydia pneumoniae DnaK protein homolog |
| Q37894914 | Sequence analysis of the major outer membrane protein gene of Chlamydia pneumoniae |
| Q36546292 | Serological cross-reactions between Bartonella and Chlamydia species: implications for diagnosis |
| Q37132394 | Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. |
| Q37884209 | Serological response to Chlamydia pneumoniae in patients with sarcoidosis |
| Q37868059 | Seroprevalence of Chlamydia pneumoniae infection in Taiwan |
| Q36731584 | Severe asthma exacerbation: role of acute Chlamydophila pneumoniae and Mycoplasma pneumoniae infection |
| Q36973222 | Similarity of Chlamydia pneumoniae strains in the variable domain IV region of the major outer membrane protein gene |
| Q37858428 | Simultaneous detection of Chlamydophila pneumoniae and Mycoplasma pneumoniae by use of molecular beacons in a duplex real-time PCR |
| Q35764383 | Specificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: evaluation of the innocent bystander hypothesis |
| Q37893998 | Spread of subclinical Chlamydia pneumoniae infection in a closed community |
| Q37853293 | Stability of Chlamydophila pneumoniae in a harsh environment without a requirement for acanthamoebae |
| Q31029781 | Structural analyses of the lipopolysaccharides from Chlamydophila psittaci strain 6BC and Chlamydophila pneumoniae strain Kajaani 6. |
| Q37890783 | Structural analysis of two oligosaccharide bisphosphates isolated from the lipopolysaccharide of a recombinant strain of Escherichia coli F515 (Re chemotype) expressing the genus‐specific epitope of Chlamydia lipopolysaccharide |
| Q24816884 | Sudden psychotic episode probably due to meningoencephalitis and Chlamydia pneumoniae acute infection |
| Q37873270 | Survival of Chlamydia pneumoniae-infected Mono Mac 6 cells is dependent on NF-kappaB binding activity |
| Q37888689 | Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia |
| Q37883672 | Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations |
| Q50536631 | Symptoms of chronic bronchitis and the risk of coronary disease. |
| Q37875251 | The Role of Chlamydia in Upper Respiratory Tract Infections |
| Q37873971 | The adventitia of atherosclerotic coronary arteries frequently contains Chlamydia pneumoniae |
| Q34075142 | The association of infection and coronary artery disease: an update |
| Q33843538 | The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae |
| Q37846201 | The chlamydial OTU domain-containing protein ChlaOTU is an early type III secretion effector targeting ubiquitin and NDP52. |
| Q33558862 | The effect of proatherogenic pathogens on adipose tissue transcriptome and fatty acid distribution in apolipoprotein E-deficient mice |
| Q71692286 | The frequency of resistance to erythromycin in group A streptococci in Ankara |
| Q36540234 | The future role and importance of macrolides |
| Q36630577 | The molecular basis for disease phenotype in chronic Chlamydia-induced arthritis |
| Q37837847 | The novel chlamydial adhesin CPn0473 mediates the lipid raft-dependent uptake of Chlamydia pneumoniae |
| Q27485617 | The origin of major human infections and the crucial role of person-to-person spread |
| Q43424431 | The prevalence of Chlamydia pneumoniae in respiratory infections in the lower respiratory tracts in children under two |
| Q77936256 | The spectrum of skin, mucosa and other extra-articular manifestations |
| Q27825840 | The transcriptional landscape of Chlamydia pneumoniae |
| Q34067823 | The use of serologic tests for the diagnosis of chlamydial infections |
| Q53431488 | Toward a unifying hypothesis in the development of Alzheimer's disease. |
| Q37884498 | Treatment of acute bronchitis in adults without underlying lung disease |
| Q37873600 | Trial of roxithromycin in subjects with asthma and serological evidence of infection with Chlamydia pneumoniae |
| Q37892713 | Use of HEp-2 cells for improved isolation and passage of Chlamydia pneumoniae |
| Q37876328 | Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection |
| Q33672291 | Use of lambda phage DNA as a hybrid internal control in a PCR-enzyme immunoassay to detect Chlamydia pneumoniae |
| Q37849535 | Vaccination of healthy and diseased koalas (Phascolarctos cinereus) with a Chlamydia pecorum multi-subunit vaccine: evaluation of immunity and pathology |
| Q34419634 | What diagnostic tests are needed for community-acquired pneumonia? |
Search more.